Sens. Amy Klobuchar, D-Minn.; Richard Blumenthal, D-Conn.; Cory Booker, D-N.J.; Mazie Hirono, D-Hawaii; Kamala Harris, D-Calif.; Elizabeth Warren, D-Mass.; Tammy Baldwin, D-Wash.; Tina Smith, D-Minn.; and Bernie Sanders, I-Vt.; yesterday urged the Federal Trade Commission to closely scrutinize pharmaceutical mergers. “In just the first half of 2019, we have seen multi-billion dollar acquisitions announced by Pfizer and Roche in addition to the proposed AbbVie and Bristol-Myers deals,” they wrote. “And reports indicate that pharmaceutical mergers and acquisitions are expected to increase. This industry consolidation is occurring against a backdrop of ever rising prescription drug spending and reports that one in four people taking prescription drugs have difficulty affording their medication. It is more important than ever that the FTC take appropriate action to protect consumers from acquisitions that may threaten competition in drug markets, raise drug prices, or reduce patient access to essential medications.”
Despite what they say about gridlock and nothing going on in Washington, there actually is a lot going on in real time that has a real impact on ou
Among other benefits to the community, mergers can help hospitals deploy more effective safeguards against hackers, writes AHA General Counsel Melinda Hatton.
There are numerous benefits to the community that derive from hospital and health system mergers, starting with quality improvements and expanding services.
AHA featured in numerous media publications.
Based on guidelines used by the Department of Justice and Federal Trade Commission to assess market competition, 75% of U.S. commercial health insurance…
Health care is experiencing unprecedented change: the field is shifting to value-based care; new players are entering the health care field; and pa